Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

被引:7
|
作者
Mosquera Orgueira, Adrian [1 ,2 ,3 ]
Antelo Rodriguez, Beatriz [1 ,2 ,3 ]
Alonso Vence, Natalia [1 ,2 ]
Bendana Lopez, Angeles [1 ,2 ]
Diaz Arias, Jose Angel [1 ,2 ]
Diaz Varela, Nicolas [2 ]
Gonzalez Perez, Marta Sonia [1 ,2 ]
Perez Encinas, Manuel Mateo [1 ,3 ]
Bello Lopez, Jose Luis [1 ,2 ,3 ]
机构
[1] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Complexo Hosp Univ Santiago de Compostela, Div Hematol, SERGAS, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
日本学术振兴会;
关键词
chronic lymphocytic leukemia; time to treatment prediction; gene expression; RNAseq; machine learning; prognostic factors; IGHV; LYMPHOMA;
D O I
10.3389/fonc.2019.00079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    SILVER, RT
    SEMINARS IN HEMATOLOGY, 1969, 6 (04) : 344 - &
  • [22] Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel
    Weil, Clara
    Chodick, Gabriel
    Shalev, Varda
    Kan, Inna
    Afik, Ran
    Cohen, Raanan
    Sail, Kavita
    Herishanu, Yair
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1136 - 1145
  • [23] New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
    Shah, Arpita
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1113 - 1122
  • [24] Chronic Lymphocytic Leukemia: Putting New Treatment Options Into Perspective
    Pinilla-Ibarz, Javier
    McQuary, Amy
    CANCER CONTROL, 2010, 17 (02) : 4 - 15
  • [25] New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia
    Gentile, M
    Mauro, FR
    Guarini, A
    Foà, R
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (06) : 597 - 604
  • [26] New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
    Awan, Farrukh T.
    Byrd, John C.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5869 - 5874
  • [27] Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm
    Molica, Stefano
    LEUKEMIA & LYMPHOMA, 2007, 48 (05) : 866 - 869
  • [28] Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia
    Awan, Farrukh T.
    Johnson, Amy J.
    Lapalombella, Rosa
    Hu, Weihong
    Lucas, Margaret
    Fischer, Beth
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 27 - 38
  • [29] New oral small molecules in the treatment of chronic lymphocytic leukemia
    Lamanna, Nicole
    CANCER, 2015, 121 (12) : 1917 - 1926
  • [30] Treatment of relapsed chronic lymphocytic leukemia: Old and new therapies
    Byrd, JC
    Lin, TS
    Grever, MR
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : 210 - 219